Alps Group Inc announced on June 23, 2026, the launch of a patient-derived organoid program to advance personalized cancer care in Southeast Asia. The company operates in the healthcare sector and provides personalized cancer care solutions.

On June 9, 2026, Alps Group Inc announced that its subsidiary, MyGenome Sdn. Bhd., received accreditation for Whole Genome Sequencing under MS ISO 15189:2022. The company operates in the healthcare industry, providing genomic testing and diagnostic services.